具有GCSF活性的噬菌体展示肽

从NFS 6 0细胞中克隆了小鼠粒细胞集落刺激因子 (granulocytecolony stimulatingfactor,G CSF)受体的细胞因子受体同源区 (cytokinereceptorhomologous ,CRH)结构域 ,采用GST融合表达策略 ,实现了CRH结构域的表达 .以纯化的GST CRH融合蛋白为靶 ,从噬菌体随机环七肽库中筛选CRH结构域的结合肽 ,找到两组具有核心序列的噬菌体展示肽 .其中C2和C13噬菌体展示肽能刺激NFS 6 0细胞增殖 ,说明C2和C13噬菌体展示肽具有G CSF活性     

抗人白细胞介素15中和抗体识别抗原表位的噬菌体肽库筛选与鉴定

目的:用噬菌体呈现随机七肽库筛选能与抗人白细胞介素15(h IL-15)中和抗体特异性结合的模拟抗原表位肽,并初步鉴定其免疫原性。方法:以抗h IL-15中和抗体为靶分子,用生物淘洗法从噬菌体呈现线性七肽库中筛选与之结合的噬菌体克隆,用噬菌体ELISA和竞争抑制ELISA鉴定阳性噬菌体克隆;化学合成筛选得到的多肽,并与匙孔血蓝蛋白(KLH)偶联免疫BALB/c小鼠,检测其免疫原性。结果:经过3轮体外筛选后随机挑取50个阳性噬菌体克隆,ELISA检测结果显示其中15个克隆与抗h IL-15抗体有较强的结合能力,DNA测序结果得到的结构相似群为MTPFWQK、MSPFNQK、MIPYWQK和MIPFHQK;竞争性ELISA结果显示4个序列均能与IL-15竞争性地结合抗IL-15单抗;小鼠免疫实验结果显示4组多肽均能诱导IL-15特异性免疫反应。结论:筛选得到能与抗h IL-15中和抗体特异性结合,且具有免疫原性的模拟抗原7肽序列,为进一步开发h IL-15相关的多肽疫苗提供了依据。     

趋化因子受体 CCR5 亲合短肽的筛选

趋化因子受体 5 (CCR5) 是 HIV-1 与宿主细胞结合的辅助因子之一,其功能缺失或被 CCR5 拮抗剂封闭则会阻止 HIV-1 感染细胞 . 为得到与 CCR5 特异结合的肽类拮抗剂,采用噬菌体展示技术,以稳定表达 CCR5 的 CHO 细胞 (CHO/CCR5) 作为靶标,通过噬菌体随机 12 肽库筛选与 CCR5 特异结合的多肽;经过四轮筛选后,挑选 20 个阳性噬菌体克隆进行测序,从中得到 11 个含有 AFDWTFVPSLIL 序列的小分子肽 . 含该序列的噬菌体能与抗人 CCR5 单抗 (2D7) 竞争性结合 CCR5 ,且合成肽 AFDWTFVPSLIL 对趋化因子 RANTES 与 CHO/CCR5 的结合具有明显的抑制作用,初步证明该小肽与 CCR5 具有特异性结合作用 .     

核受体PPARγ结合小肽的筛选及其功能

为筛选与核受体过氧化物酶体增殖物激活受体γ(PPARγ)结合的功能短肽,在大肠杆菌BL21(DE3)中表达PPARγ配体结合域(LBD)的融合蛋白,并利用Ni2+-NTA离子交换树脂对表达蛋白进行纯化.以此纯化蛋白为靶,采用固体包被法对噬菌体展示随机十二肽库及环七肽库进行亲和筛选.经ELISA法鉴定特异结合的高亲和力阳性噬菌体单克隆并测序.同时利用PPARγ的配体rosiglitazone与噬菌体小肽进行竞争性结合抑制实验.最终获得与PPARγ-LBD高亲和力的十二肽3个,环七肽5个,分别含LXXLL和DXXRW(其中X为非特异氨基酸残基)保守序列.Rosiglitazone不影响噬菌体小肽与靶蛋白的结合,说明获得与配体rosiglitazone结合位点不同的目的肽.     

人白细胞介素-2功能性受体在小鼠细胞可重建

白细胞介素-2(IL-2)与其受体相互作用,可促进已活化的T 细胞生长,但只当IL-2与高亲和性受体结合才能释放与生长相关的传导信号。作者从正常人用合成的寡聚核苷酸探针筛选出编码IL-2受体特异的基因克隆。筛选出的数个阳性克隆中,P~(IL-2R)-6克隆经分析发现能编码成人T 细胞白血病细胞表达的IL-2受体的全部序列。作者为了使IL-2受体cDNA 在哺乳细胞中稳定表达,构建了一个P~(SVIL-2R)-3质粒,并     

从噬菌体表面展示肽库中筛选志贺毒素受体结合抑制剂

利用抗体捕获法 ,从表面展示随机肽序列的噬菌体文库中筛选到与志贺毒素B亚基 (StxB)结合 ,并能抑制志贺毒素细胞毒效应的噬菌体克隆 ;依据其中 1个克隆序列 (A12 )合成的肽可以与志贺毒素的受体Gb3竞争结合StxB ,并抑制志贺毒素(Stx)的细胞毒和肠毒活性 ;抑制 5×CD₅₀ 剂量的Stx细胞毒效应需 2 2 .7μmol的A12合成肽 .筛选得到的 2个噬菌体克隆 (A3 ,A12 )编码的氨基酸序列不同 ,但能竞争结合StxB ,推测它们形成相同或相似的空间结构 .为志贺毒素抑制剂进一步研究打下基础 ,对其他相关药物的研制亦有参考价值 .     

7肽和12肽两种M13噬菌体展示库筛选肿瘤坏死因子alpha拮抗肽的比较

肿瘤坏死因子alpha的拮抗剂是治疗多种炎症性自身免疫疾病的首选,但抗体类拮抗物因副作用明显而使用受限,尤其是机体内抗抗体的产生,严重影响治疗效果和药物代谢。而肽类物除免疫原性低之外,和小分子相比也有更低的毒性和更强的靶标特异性。使用7肽和12肽两种M13噬菌体展示库筛选TNFα拮抗肽,以分析7肽和12肽分别作为TNFα拮抗肽的亲和性与功能性。经过3~4轮的筛选和验证,得到2条7肽序列和2条12肽序列。利用ELISA方法检测合成肽与TNFα结合的亲和性,编号632的7肽亲和性最强,Kd=138nmol/L;编号636的12肽亲和性稍差,Kd=8.59μmol/L。InsightⅡ软件分别分析632肽和636肽与TNFα二聚体结合,发现632肽与TNFα二聚体结合更加稳定,并且在细胞水平上632肽拮抗TNFα活性功能比636肽更强,有632肽存在的条件下TNFα诱导的L929细胞生存率上升了3倍,而636肽的作用只有2倍。7肽比12肽更适合作为TNFα拮抗肽。     

从七肽噬菌体展示库中筛选内毒素结合蛋白质配基

目的:研究从噬茵体展示库中筛选内毒素结合蛋白质配基,为其在内毒素致病作用机理及在内毒素血症防治研究中的应用奠定基础.方法:以内毒素为靶分子从随机七肽噬菌体展示库中筛选内毒素的高亲和力噬菌体配体,通过ELISA鉴定,DNA测序及相关软件分析.结果:所筛选的亲和力最高的噬菌体的ELISA检测值A405nm可达1.965通过比较亲和性噬菌体外源插入肽的DNA序列,认为FHENWPS肽段中包含有与内毒素分子发生亲和结合的一个共有序列.该序列展示肽的等电点为5.36,具有双嗜性,这有利于肽与LPS分子表面的位点相互作用从而产生亲和吸附.结论:运用亲和筛选方法从肽库中筛选内毒素结合蛋白质配基是可行的.     

人白细胞介素2受体(IL-2R)cDNA在哺乳类细胞中表达的初步研究

按DNA-磷酸钙共沉淀法将人白细胞介素2受体(IL-2R)cDNA转染小鼠成纤维细胞L929,经RNA点渍杂交分析、荧光标记IL-2染色和抗Tac(人IL-2受体α链)特异性玫瑰花环试验,均证明转入的IL-2R cDNA在L929细胞中表达,其产物具有结合IL-2和抗Tac抗体的能力。本文还报道了T细胞白血病Jukat细胞和Molt-4等细胞系异常表达IL-2R的结果,并对此作了分析和讨论。     

神经生长因子低亲和力受体(p75NTR)的模拟配基的筛选

人神经生长因子低亲和力受体 (p75NTR)转染R2细胞而建立的R2L1细胞 ,在去血清培养时发生凋亡 ,该作用可被神经生长因子 (NGF)所抑制 .用R2L1和R2两种细胞差式筛选噬菌体随机 7肽库和 1 2肽库 ,获得和p75NTR特异结合的噬菌体 .测定DNA序列后得到有关多肽的氨基酸序列 .7肽库共有序列为C (H D)LP(K M)HPM C ;1 2肽库优势序列为TLPSPLALLTVH .化学合成相应的 2个短肽 .用细胞结合法和ELISA方法证实阳性噬菌体和合成短肽能与p75NTR结合 ,并证实了它们对R2L1细胞去血清培养后的凋亡有抑制作用     

IL‐27 Rα+ cells promoted allorejection via enhancing STAT1/3/5 phosphorylation

Recently, emerging evidence strongly suggested that the activation of interleukin‐27 Receptor α (IL‐27Rα) could modulate different inflammatory diseases. However, whether IL‐27Rα affects allotransplantation rejection is not fully understood. Here, we investigated the role of IL‐27Rα on allorejection both in vivo and in vitro. The skin allotransplantation mice models were established, and the dynamic IL‐27Rα/IL‐27 expression was detected, and IL‐27Rα⁺ spleen cells adoptive transfer was performed. STAT1/3/5 phosphorylation, proliferation and apoptosis were investigated in mixed lymphocyte reaction (MLR) with recombinant IL‐27 (rIL‐27) stimulation. Finally, IFN‐γ/ IL‐10 in graft/serum from model mice was detected. Results showed higher IL‐27Rα/IL‐27 expression in allografted group compared that syngrafted group on day 10 (top point of allorejection). IL‐27Rα⁺ spleen cells accelerated allograft rejection in vivo. rIL‐27 significantly promoted proliferation, inhibited apoptosis and increased STAT1/3/5 phosphorylation of alloreactive splenocytes, and these effects of rIL‐27 could be almost totally blocked by JAK/ STAT inhibitor and anti‐IL‐27 p28 Ab. Finally, higher IL‐27Rα⁺IFN‐γ⁺ cells and lower IL‐27Rα⁺IL‐10⁺ cells within allografts, and high IFN‐γ/low IL‐10 in serum of allorejecting mice were detected. In conclusion, these data suggested that IL‐27Rα⁺ cells apparently promoted allograft rejection through enhancing alloreactive proliferation, inhibiting apoptosis and up‐regulating IFN‐γ via enhancing STAT pathway. Blocking IL‐27 pathway may favour to prevent allorejection, and IL‐27Rα may be as a high selective molecule for targeting diagnosis and therapy for allotransplantation rejection.     

Structural determinants of affinity enhancement between GoLoco motifs and G-protein alpha subunit mutants

GoLoco motif proteins bind to the inhibitory G(i) subclass of G-protein α subunits and slow the release of bound GDP; this interaction is considered critical to asymmetric cell division and neuro-epithelium and epithelial progenitor differentiation. To provide protein tools for interrogating the precise cellular role(s) of GoLoco motif/Gα(i) complexes, we have employed structure-based protein design strategies to predict gain-of-function mutations that increase GoLoco motif binding affinity. Here, we describe fluorescence polarization and isothermal titration calorimetry measurements showing three predicted Gα(i1) point mutations, E116L, Q147L, and E245L; each increases affinity for multiple GoLoco motifs. A component of this affinity enhancement results from a decreased rate of dissociation between the Gα mutants and GoLoco motifs. For Gα(i1)(Q147L), affinity enhancement was seen to be driven by favorable changes in binding enthalpy, despite reduced contributions from binding entropy. The crystal structure of Gα(i1)(Q147L) bound to the RGS14 GoLoco motif revealed disorder among three peptide residues surrounding a well defined Leu-147 side chain. Monte Carlo simulations of the peptide in this region showed a sampling of multiple backbone conformations in contrast to the wild-type complex. We conclude that mutation of Glu-147 to leucine creates a hydrophobic surface favorably buried upon GoLoco peptide binding, yet the hydrophobic Leu-147 also promotes flexibility among residues 511-513 of the RGS14 GoLoco peptide.     

Elevated titers of cell-free interleukin 2 receptor in serum of lupus mice

Activation/proliferation of mouse and human T and B cells is associated with expression and subsequent release of interleukin 2 receptors (IL 2R) into the milieu. The soluble form of IL 2R, at least in part, retains its ability to bind to IL 2 and to anti-receptor antibodies, but its exact structure remains unknown. Because systemic lupus erythematosus (SLE) is associated with T and B cell activation, we have used monoclonal anti-IL 2R antibodies in an ELISA to measure levels of IL 2R in sera of various lupus strains. High levels of the released receptor were found at an active clinical stage in sera of four autoimmune strains of mice homozygous for the lpr (lymphoproliferation) gene that causes T cell expansion, massive lymphoid organ enlargement, and promotes the autoimmune process. High levels were also found in lupus mice characterized primarily by B cell proliferation (BXSB males) and in (NZB X W)F1 mice characterized by T and B cell activation. Similarly high IL 2R serum levels could be induced experimentally in normal mice injected with immunostimulants such as bacterial lipopolysaccharide or Freund's complete adjuvant. The results indicate that IL 2R serum levels may provide a good marker of ongoing lymphoid cell activation/proliferation, and thus might be useful in the follow-up of patients with systemic autoimmune or other lymphoproliferative disorders. The biologic roles, if any, of the soluble form of IL 2R and its effects in normal and abnormal conditions remain to be determined.     

Peptide substrates for Rho-associated kinase 2 (Rho-kinase 2/ROCK2)

Peptide substrates sensitive for a certain protein kinase could be important for new-drug development and to understand the mechanism of diseases. Rho-associated kinase (Rho-kinase/ROCK) is a serine/threonine kinase, and plays an important part in cardiovascular disease, migration and invasion of tumor cells, and in neurological disorders. The purpose of this study was to find substrates with high affinity and sensitivity for ROCK2. We synthesized 136 peptide substrates from protein substrates for ROCK2 with different lengths and charged peptides. Incorporation of (32)P [counts per minute (CPM)] for each peptide substrate was determined by the radiolabel assay using [γ-(32)P]ATP. When the top five peptide substrates showing high CPMs (R4, R22, R133, R134, and R135) were phosphorylated by other enzymes (PKA, PKCα, and ERK1), R22, R133, and R135 displayed the highest CPM level for ROCK2 compared with other enzymes, whereas R4 and R134 showed similar CPM levels for ROCK2 and PKCα. We hypothesize that R22, R133, and R135 can be useful peptide substrates for ROCK2.     

Interleukin 13 receptor alpha 2 (IL13Rα2): Expression,signaling pathways and therapeutic applications in cancer

Interleukin 13 receptor alpha 2 (IL13Rα2) is increasingly recognized as a relevant player in cancer invasion and metastasis. Despite being initially considered a decoy receptor for dampening the levels of interleukin 13 (IL-13) in diverse inflammatory conditions, accumulating evidences in the last decades indicate the capacity of IL13Rα2 for mediating IL-13 signaling in cancer cells. The biological reasons behind the expression of this receptor with such extremely high affinity for IL-13 in cancer cells remain unclear. Elevated expression of IL13Rα2 is commonly associated with invasion, late stage and cancer metastasis that results in poor prognosis for glioblastoma, colorectal or breast cancer, among others. The discovery of new mediators and effectors of IL13Rα2 signaling has been critical for deciphering its underlying molecular mechanisms in cancer progression. Still, many questions about the effects of inflammation, the cancer type and the tumor degree in the expression of IL13Rα2 remain largely uncharacterized. Here, we review and discuss the current status of the IL13Rα2 biology in cancer, with particular emphasis in the role of inflammation-driven expression and the regulation of different signaling pathways. As IL13Rα2 implications in cancer continue to grow exponentially, we highlight new targeted therapies recently developed for glioblastoma, colorectal cancer and other IL13Rα2-positive tumors.     

Characterization and Immunotherapeutic Implications for a Novel Antibody Targeting Interleukin (IL)-13 Receptor α2

The high affinity interleukin-13 receptor α2 (IL13Rα2) is selectively expressed at a high frequency by glioblastoma multiforme (GBM) as well as several other tumor types. One approach for targeting this tumor-specific receptor utilizes the cognate ligand, IL-13, conjugated to cytotoxic molecules. However, this approach lacks specificity because the lower affinity receptor for IL-13, IL13Rα1, is widely expressed by normal tissues. Here, we aimed to develop and characterize a novel monoclonal antibody (mAb) specific to IL13Rα2 for the therapeutic purpose of targeting IL13Rα2-expressing tumors. Hybridoma cell lines were generated and compared for binding affinities to recombinant human IL13Rα2 (rhIL13Rα2). Clone 47 demonstrated binding to the native conformation of IL13Rα2 and was therefore chosen for further studies. Clone 47 bound specifically and with high affinity (K(D) = 1.39 × 10(-9) m) to rhIL13Rα2 but not to rhIL13Rα1 or murine IL13Rα2. Furthermore, clone 47 specifically recognized wild-type IL13Rα2 expressed on the surface of CHO and HEK cells as well as several glioma cell lines. Competitive binding assays revealed that clone 47 also significantly inhibited the interaction between human soluble IL-13 and IL13Rα2 receptor. Moreover, we found that N-linked glycosylation of IL13Rα2 contributes in part to the interaction of the antibody to IL13Rα2. In vivo, the IL13Rα2 mAb improved the survival of nude mice intracranially implanted with a human U251 glioma xenograft. Collectively, these data warrant further investigation of this novel IL13Rα2 mAb with an emphasis on translational implications for therapeutic use.     

Structural Basis of Interleukin-5 Inhibition by the Small Cyclic Peptide AF17121

Interleukin-5 (IL-5) is a T-helper cell of subtype 2 cytokine involved in many aspects of eosinophil life. Eosinophilic granulocytes play a pathogenic role in the progression of atopic diseases, such as allergy, asthma and atopic dermatitis and hypereosinophilic syndromes. Here, eosinophils upon activation degranulate leading to the release of proinflammatory proteins and mediators stored in intracellular vesicles termed granula thereby causing local inflammation, which when persisting leads to tissue damage and organ failure. As a key regulator of eosinophil function, IL-5 therefore presents a major pharmaceutical target and approaches to interfere with IL-5 receptor activation are of great interest. Here we present the structure of the IL-5 inhibiting peptide AF17121 bound to the extracellular domain of the IL-5 receptor IL-5Rα. The small 18mer cyclic peptide snugly fits into the wrench-like cleft of the IL-5 receptor, thereby blocking access of key residues for IL-5 binding. While AF17121 and IL-5 seemingly bind to a similar epitope at IL-5Rα, functional studies show that recognition and binding of both ligands differ. Using the structure data, peptide variants with improved IL-5 inhibition have been generated, which might present valuable starting points for superior peptide-based IL-5 antagonists.